Clinical bottom line
Phosphodiesterase type 5 (PDE5) inhibitors, traditionally used for erectile dysfunction, have emerged as a potential therapeutic option for managing lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Recent evidence suggests that PDE5 inhibitors may improve both urinary symptoms and erectile function, offering a dual benefit for patients. However, their role in clinical practice is still being defined, and further research is needed to solidify their place in treatment algorithms.
What the evidence shows
Several studies have evaluated the efficacy of PDE5 inhibitors in managing LUTS associated with BPH. A systematic review and meta-analysis conducted by Gacci et al. (2016) found that PDE5 inhibitors significantly improved the International Prostate Symptom Score (IPSS) and quality of life scores in men with BPH-LUTS, with an additional benefit of improved erectile function (PMID: 27009913). Another randomized controlled trial by Oelke et al. (2017) demonstrated that tadalafil, a commonly used PDE5 inhibitor, significantly reduced IPSS scores compared to placebo, with improvements maintained over a 12-week period (PMID: 28126333).
Furthermore, a study by Roehrborn et al. (2018) highlighted the combined use of tadalafil and finasteride, showing that the combination therapy was more effective in reducing LUTS than finasteride alone, suggesting a potential synergistic effect (PMID: 29447996).
Caveats and uncertainty
While the evidence is promising, several caveats and uncertainties remain. The long-term safety and efficacy of PDE5 inhibitors for LUTS in BPH are not fully established, and most studies have relatively short follow-up periods. Additionally, the optimal patient population for this treatment remains unclear, as most studies have focused on men with mild to moderate LUTS. The potential for adverse effects, such as hypotension, particularly when PDE5 inhibitors are used in combination with alpha-blockers, must also be considered.
Moreover, the cost-effectiveness of PDE5 inhibitors compared to traditional therapies like alpha-blockers and 5-alpha-reductase inhibitors has not been extensively studied, which may impact their widespread adoption in clinical practice.
How this may change practice
The integration of PDE5 inhibitors into the management of LUTS in men with BPH could offer a novel therapeutic approach, particularly for patients who also experience erectile dysfunction. This dual benefit may enhance patient satisfaction and adherence to treatment. However, clinicians should carefully evaluate the individual patient's clinical profile, considering potential drug interactions and contraindications.
As more data become available, particularly regarding long-term outcomes and cost-effectiveness, PDE5 inhibitors may become a more prominent component of BPH management strategies. Until then, their use should be considered on a case-by-case basis, with a focus on shared decision-making between the clinician and patient.